Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has granted 510(k) clearance for the Biolinq Shine, a needle-free continuous glucose monitor (CGM) now available over the counter. The device uses tiny microsensors placed on the forearm — no needle required — and features a color-coded LED screen to show real-time glucose levels. It's designed for adults 22 and older who don't use insulin.
The FDA has granted 510(k) clearance for the Biolinq Shine, making it the latest continuous glucose monitor (CGM) available over the counter — and the first needle-free option in the space. Made by Biolinq Inc., the device uses microsensors that sit on the skin's surface and can be worn on the forearm without any needle insertion. It's intended for adults aged 22 and older who do not use insulin.
The Biolinq Shine displays real-time glucose levels via a color-coded LED screen, letting users instantly see whether they're in, above, or below their target range — no phone required. An optional companion app adds deeper insights into how sleep, physical activity, and eating habits affect blood sugar. The device originally received FDA de novo classification in 2025, and this new clearance now allows it to be sold without a prescription.
Key Takeaways:
Why it matters: As CGM technology moves beyond diabetes management into everyday wellness, needle-free and prescription-free options could significantly expand who monitors their metabolic health — putting real-time glucose data in the hands of millions more people.
